{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-24-000062","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.890575+00:00","generated_at":"2026-05-30T08:03:05.250552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Rad Q3 revenue up 2.8% to $649.7M; net income $653.2M on Sartorius gain","bullets":["Net sales $649.7M, +2.8% YoY; currency-neutral +3.4%; Clinical Diagnostics grew 5.6% to $388.8M.","Life Science segment sales $260.9M, -1.0% YoY, citing ongoing biotech/biopharma weakness.","Income from operations fell to $64.5M from $90.9M; net income surged to $653.2M ($23.34 EPS) on Sartorius fair value change.","Gross margin improved to 54.8% from 53.1% YoY; effective tax rate 24.2%.","Appointed Jon DiVincenzo as President and COO; CEO cites gradual biopharma recovery and new leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-24-000062","json":"https://secwatch.observer/filing/0000012208-24-000062.json","markdown":"https://secwatch.observer/filing/0000012208-24-000062.md","text":"https://secwatch.observer/filing/0000012208-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000062/0000012208-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000062/bio-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:03:05.250552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}